Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation

The pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk facto...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 1081942
Main Authors Zhang, Binshan, Xing, Guolan
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 13.12.2022
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2022.1081942

Cover

Abstract The pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk factors for renal survival between patients with or without TMA in LN cohorts. We included 79 patients with biopsy-proven LN-associated TMA and matched the same number of LN patients without TMA as the control group. The deposition of mannose binding lectin (MBL), MBL-associated serine proteases 1/3 (MASP1/3), complement factor B (CFB), complement factor D (CFD), C4d, and von Willebrand factor (VWF) in renal tissue was assessed by immunohistochemistry and immunofluorescence. Besides, co-localization of C5b-9 and CD34 was detected by confocal microscopy. In our retrospective cohort, the incidence of acute kidney injury (30% vs. 14%, p = 0.013), acute hemodialysis (35% vs. 5%, p < 0.001), and interstitial fibrosis (43% vs. 13%, p < 0.001) is higher in the TMA, compared with the control group. Despite aggressive steroids pulse, plasma exchange, and immunosuppressive therapy among TMA group, they still had significantly inferior 3-year renal survival rates (68% vs. 89%, p = 0.002) than those in the non-TMA group. COX regression analysis identified that TMA (HR 4.807, 95% CI [2.052, 11.263], p < 0.001) is a risk factor in LN. MBL, MASP1/3, CFB, CFD, C4d, and VWF deposited along the glomerulus among LN, while TMA had stronger staining intensity and deposition. The co-localized expression of CD34 and C5b-9 in the endothelial cells was also observed in the renal tissues. TMA is an independent risk factor for renal survival in LN patients. Moreover, LP and AP activation are involved in the pathogenesis of LN-associated TMA.
AbstractList ObjectiveThe pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk factors for renal survival between patients with or without TMA in LN cohorts.MethodsWe included 79 patients with biopsy-proven LN-associated TMA and matched the same number of LN patients without TMA as the control group. The deposition of mannose binding lectin (MBL), MBL-associated serine proteases 1/3 (MASP1/3), complement factor B (CFB), complement factor D (CFD), C4d, and von Willebrand factor (VWF) in renal tissue was assessed by immunohistochemistry and immunofluorescence. Besides, co-localization of C5b-9 and CD34 was detected by confocal microscopy.ResultsIn our retrospective cohort, the incidence of acute kidney injury (30% vs. 14%, p = 0.013), acute hemodialysis (35% vs. 5%, p < 0.001), and interstitial fibrosis (43% vs. 13%, p < 0.001) is higher in the TMA, compared with the control group. Despite aggressive steroids pulse, plasma exchange, and immunosuppressive therapy among TMA group, they still had significantly inferior 3-year renal survival rates (68% vs. 89%, p = 0.002) than those in the non-TMA group. COX regression analysis identified that TMA (HR 4.807, 95% CI [2.052, 11.263], p < 0.001) is a risk factor in LN. MBL, MASP1/3, CFB, CFD, C4d, and VWF deposited along the glomerulus among LN, while TMA had stronger staining intensity and deposition. The co-localized expression of CD34 and C5b-9 in the endothelial cells was also observed in the renal tissues.ConclusionsTMA is an independent risk factor for renal survival in LN patients. Moreover, LP and AP activation are involved in the pathogenesis of LN-associated TMA.
The pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk factors for renal survival between patients with or without TMA in LN cohorts. We included 79 patients with biopsy-proven LN-associated TMA and matched the same number of LN patients without TMA as the control group. The deposition of mannose binding lectin (MBL), MBL-associated serine proteases 1/3 (MASP1/3), complement factor B (CFB), complement factor D (CFD), C4d, and von Willebrand factor (VWF) in renal tissue was assessed by immunohistochemistry and immunofluorescence. Besides, co-localization of C5b-9 and CD34 was detected by confocal microscopy. In our retrospective cohort, the incidence of acute kidney injury (30% vs. 14%, p = 0.013), acute hemodialysis (35% vs. 5%, p < 0.001), and interstitial fibrosis (43% vs. 13%, p < 0.001) is higher in the TMA, compared with the control group. Despite aggressive steroids pulse, plasma exchange, and immunosuppressive therapy among TMA group, they still had significantly inferior 3-year renal survival rates (68% vs. 89%, p = 0.002) than those in the non-TMA group. COX regression analysis identified that TMA (HR 4.807, 95% CI [2.052, 11.263], p < 0.001) is a risk factor in LN. MBL, MASP1/3, CFB, CFD, C4d, and VWF deposited along the glomerulus among LN, while TMA had stronger staining intensity and deposition. The co-localized expression of CD34 and C5b-9 in the endothelial cells was also observed in the renal tissues. TMA is an independent risk factor for renal survival in LN patients. Moreover, LP and AP activation are involved in the pathogenesis of LN-associated TMA.
The pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk factors for renal survival between patients with or without TMA in LN cohorts.ObjectiveThe pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement lectin pathway (LP) and alternative pathway (AP) components in renal tissues, then evaluate the clinicopathological characteristics and risk factors for renal survival between patients with or without TMA in LN cohorts.We included 79 patients with biopsy-proven LN-associated TMA and matched the same number of LN patients without TMA as the control group. The deposition of mannose binding lectin (MBL), MBL-associated serine proteases 1/3 (MASP1/3), complement factor B (CFB), complement factor D (CFD), C4d, and von Willebrand factor (VWF) in renal tissue was assessed by immunohistochemistry and immunofluorescence. Besides, co-localization of C5b-9 and CD34 was detected by confocal microscopy.MethodsWe included 79 patients with biopsy-proven LN-associated TMA and matched the same number of LN patients without TMA as the control group. The deposition of mannose binding lectin (MBL), MBL-associated serine proteases 1/3 (MASP1/3), complement factor B (CFB), complement factor D (CFD), C4d, and von Willebrand factor (VWF) in renal tissue was assessed by immunohistochemistry and immunofluorescence. Besides, co-localization of C5b-9 and CD34 was detected by confocal microscopy.In our retrospective cohort, the incidence of acute kidney injury (30% vs. 14%, p = 0.013), acute hemodialysis (35% vs. 5%, p < 0.001), and interstitial fibrosis (43% vs. 13%, p < 0.001) is higher in the TMA, compared with the control group. Despite aggressive steroids pulse, plasma exchange, and immunosuppressive therapy among TMA group, they still had significantly inferior 3-year renal survival rates (68% vs. 89%, p = 0.002) than those in the non-TMA group. COX regression analysis identified that TMA (HR 4.807, 95% CI [2.052, 11.263], p < 0.001) is a risk factor in LN. MBL, MASP1/3, CFB, CFD, C4d, and VWF deposited along the glomerulus among LN, while TMA had stronger staining intensity and deposition. The co-localized expression of CD34 and C5b-9 in the endothelial cells was also observed in the renal tissues.ResultsIn our retrospective cohort, the incidence of acute kidney injury (30% vs. 14%, p = 0.013), acute hemodialysis (35% vs. 5%, p < 0.001), and interstitial fibrosis (43% vs. 13%, p < 0.001) is higher in the TMA, compared with the control group. Despite aggressive steroids pulse, plasma exchange, and immunosuppressive therapy among TMA group, they still had significantly inferior 3-year renal survival rates (68% vs. 89%, p = 0.002) than those in the non-TMA group. COX regression analysis identified that TMA (HR 4.807, 95% CI [2.052, 11.263], p < 0.001) is a risk factor in LN. MBL, MASP1/3, CFB, CFD, C4d, and VWF deposited along the glomerulus among LN, while TMA had stronger staining intensity and deposition. The co-localized expression of CD34 and C5b-9 in the endothelial cells was also observed in the renal tissues.TMA is an independent risk factor for renal survival in LN patients. Moreover, LP and AP activation are involved in the pathogenesis of LN-associated TMA.ConclusionsTMA is an independent risk factor for renal survival in LN patients. Moreover, LP and AP activation are involved in the pathogenesis of LN-associated TMA.
Author Zhang, Binshan
Xing, Guolan
AuthorAffiliation Department of nephrology, First Affiliated Hospital of Zhengzhou University , Zhengzhou , China
AuthorAffiliation_xml – name: Department of nephrology, First Affiliated Hospital of Zhengzhou University , Zhengzhou , China
Author_xml – sequence: 1
  givenname: Binshan
  surname: Zhang
  fullname: Zhang, Binshan
– sequence: 2
  givenname: Guolan
  surname: Xing
  fullname: Xing, Guolan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36582241$$D View this record in MEDLINE/PubMed
BookMark eNp9kj1vHCEQhleRo9hx_AdSRJRp7sLXstBEiqx8WLKUxqnRwLJ3WLuwAfYil_nn4T5i2SlCA5p55xlg3tfNWYjBNc1bgteMSfVh8NO0rCmmdE2wJIrTF80FEYKvGKX87Mn5vLnK-R7XxRVjrH3VnDPRypohF83vu22Kk4nFWzR5myKEjY8zlO0DmlzvobiM5hgTmlPchJh9RjDFsEHjMi8ZBTdvky81uvOAbJzm0U0uFDQ6W3xAEHoEY3EpQPE7h_bkX_CAoGZ3NRTDm-blAGN2V6f9svnx5fPd9bfV7fevN9efbleWKVlWknR0oK3rLfTOCsM4o8ZINvRdLwwWrueYGEsJk5wSKjFRyjEiWxCq5R1hl83NkdtHuNdz8hOkBx3B60Mgpo2GVL9hdBosFlyBIgITTlsqBeXMmIFbYyq3r6yPR9a8mPpLtj44wfgM-jwT_FZv4k6rTlHV4Qp4fwKk-HNxuejJZ-vGEYKLS9a0a5VqOyr20ndPez02-TvDKqBHQZ1ezskNjxKC9d4r-uAVvfeKPnmlFsl_iqwvh3nU-_rxf6V_AClIyMA
CitedBy_id crossref_primary_10_1093_ckj_sfae212
crossref_primary_10_1146_annurev_med_042921_102405
crossref_primary_10_1007_s11255_023_03715_w
crossref_primary_10_1016_j_clim_2023_109735
crossref_primary_10_3389_fimmu_2024_1453030
crossref_primary_10_1007_s13730_025_00978_3
crossref_primary_10_3390_ijms25168981
crossref_primary_10_47360_1995_4484_2024_55_64
crossref_primary_10_1177_23247096251316364
crossref_primary_10_1136_lupus_2023_000996
Cites_doi 10.1111/cei.13497
10.1002/art.1780350606
10.1136/ard-2022-223035
10.1073/pnas.1202588109
10.1056/NEJMra1312353
10.1016/j.kint.2021.05.021
10.2215/cjn.00620117
10.1056/NEJMra1100359
10.1053/j.ackd.2019.10.003
10.1038/s41584-020-0401-9
10.1016/j.humimm.2013.04.030
10.3389/fimmu.2016.00055
10.1016/j.trsl.2022.03.005
10.3899/jrheum.141163
10.1146/annurev-med-061813-013241
10.1056/NEJMoa2023386
10.1016/j.biopha.2022.113433
10.1681/asn.2014050429
10.1056/nejm200104053441406
10.1007/s11033-011-1361-6
10.1177/0961203311422093
10.1681/asn.V481499
10.1002/art.40930
10.1038/srep31877
10.1007/s10067-020-05499-1
10.1016/j.autrev.2022.103072
10.1016/j.kint.2017.11.023
10.1681/asn.2005080868
10.3389/fimmu.2021.654652
10.1186/s12882-020-01888-5
10.1186/ar4142
10.1681/asn.2010060647
10.1038/nrneph.2012.195
10.1016/j.molimm.2014.06.030
10.1084/jem.20090633
10.1191/0961203305lu2238oa
10.1038/s41584-021-00739-3
10.4049/jimmunol.1501717
10.1681/asn.2013010026
10.1177/0961203310368409
10.4049/jimmunol.164.2.786
10.1038/ki.2012.409
10.1111/j.1523-1755.2004.00371.x
10.3899/jrheum.180773
10.1177/0961203310376523
10.1182/bloodadvances.2018019596
10.1016/s0272-6386(12)80885-7
10.1177/0961203311415561
10.2215/cjn.06230614
10.1038/nrneph.2012.141
10.1038/nrneph.2017.85
10.1182/blood-2016-10-709857
10.1080/0886022x.2019.1702057
10.1016/0002-9343(83)90338-8
10.1097/00005792-199709000-00003
10.3389/fimmu.2021.690821
ContentType Journal Article
Copyright Copyright © 2022 Zhang and Xing.
Copyright © 2022 Zhang and Xing 2022 Zhang and Xing
Copyright_xml – notice: Copyright © 2022 Zhang and Xing.
– notice: Copyright © 2022 Zhang and Xing 2022 Zhang and Xing
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2022.1081942
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_ac0649a91601425286243bbf4cbb019d
PMC9792970
36582241
10_3389_fimmu_2022_1081942
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
CGR
CUY
CVF
ECM
EIF
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c398t-8172f25edcadec6b3432bb83fd7d6b06ed401bc2138421280199e3185a6954713
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:27:07 EDT 2025
Thu Aug 21 18:40:20 EDT 2025
Thu Sep 04 21:55:57 EDT 2025
Thu Jan 02 22:53:15 EST 2025
Thu Apr 24 23:03:33 EDT 2025
Tue Jul 01 02:13:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords alternative pathway
lupus nephritis
thrombotic microangiopathy
complement
lectin pathway
Language English
License Copyright © 2022 Zhang and Xing.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c398t-8172f25edcadec6b3432bb83fd7d6b06ed401bc2138421280199e3185a6954713
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Dong-Qing Ye, Anhui Medical University, China
Reviewed by: Masaru Kato, Hokkaido University, Japan; Koshy Nithin Thomas, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGI), India
This article was submitted to Autoimmune and Autoinflammatory Disorders: Autoimmune Disorders, a section of the journal Frontiers in Immunology
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2022.1081942
PMID 36582241
PQID 2759957260
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_ac0649a91601425286243bbf4cbb019d
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9792970
proquest_miscellaneous_2759957260
pubmed_primary_36582241
crossref_primary_10_3389_fimmu_2022_1081942
crossref_citationtrail_10_3389_fimmu_2022_1081942
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-12-13
PublicationDateYYYYMMDD 2022-12-13
PublicationDate_xml – month: 12
  year: 2022
  text: 2022-12-13
  day: 13
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2022
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Tian (B2) 2022
Kaplan (B54) 2002; 3
Dobó (B13) 2016; 6
Austin (B30) 1983; 75
Park (B49) 2018; 2
Chen (B56) 2022; 153
Bombardier (B24) 1992; 35
Brocklebank (B33) 2018; 13
(B26) 2021; 100
Scheen (B39) 2022; 21
Zheng (B51) 2015; 66
Song (B7) 2013; 15
Gregersen (B1) 2012; 8
Macedo (B10) 2016; 7
Shen (B47) 2010; 19
Wright (B53) 2020; 21
Bao (B45) 2011; 22
Józsi (B36) 2006; 17
Lee (B18) 2012; 39
Wu (B6) 2013; 83
George (B8) 2014; 371
Elhadad (B19) 2021; 203
Watanabe (B44) 2000; 164
Jayne (B55) 2021; 384
Lech (B9) 2013; 24
Nisihara (B17) 2013; 74
Maria (B3) 2020; 16
Oroszlán (B14) 2016; 196
Parra Sánchez (B52) 2022; 18
Banfi (B35) 1991; 18
Walport (B27) 2001; 344
Ding (B25) 2020; 42
Joly (B50) 2017; 129
Mejia-Vilet (B40) 2021; 40
Mathern (B15) 2015; 10
Hu (B34) 2010; 19
Aringer (B22) 2019; 71
Chua (B48) 2015; 26
Thurman (B12) 2020; 27
Sato (B42) 2011; 20
Descombes (B29) 1997; 76
Elliott (B20) 2004; 65
Héja (B11) 2012; 109
Grumach (B37) 2014; 61
Noris (B21) 2012; 8
Li (B28) 2019; 46
Aradottir (B57) 2021; 12
Ding (B32) 2021; 12
Yu (B38) 2017; 13
Takahashi (B43) 2010; 207
Appel (B5) 1994; 4
Contreras (B31) 2005; 14
Satyam (B16) 2022; 245
Troldborg (B41) 2015; 42
Tsokos (B4) 2011; 365
Bajema (B23) 2018; 93
Batal (B46) 2012; 21
References_xml – volume: 203
  start-page: 96
  year: 2021
  ident: B19
  article-title: Masp2 levels are elevated in thrombotic microangiopathies: Association with microvascular endothelial cell injury and suppression by anti-Masp2 antibody narsoplimab
  publication-title: Clin Exp Immunol
  doi: 10.1111/cei.13497
– volume: 35
  year: 1992
  ident: B24
  article-title: Derivation of the sledai. a disease activity index for lupus patients. the committee on prognosis studies in sle
  publication-title: Arthritis Rheum
  doi: 10.1002/art.1780350606
– year: 2022
  ident: B2
  article-title: Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard-2022-223035
– volume: 109
  year: 2012
  ident: B11
  article-title: Revised mechanism of complement lectin-pathway activation revealing the role of serine protease masp-1 as the exclusive activator of masp-2
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1202588109
– volume: 371
  year: 2014
  ident: B8
  article-title: Syndromes of thrombotic microangiopathy
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1312353
– volume: 100
  start-page: S1
  year: 2021
  ident: B26
  article-title: Clinical practice guideline for the management of glomerular diseases
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2021.05.021
– volume: 13
  year: 2018
  ident: B33
  article-title: Thrombotic microangiopathy and the kidney
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/cjn.00620117
– volume: 365
  year: 2011
  ident: B4
  article-title: Systemic lupus erythematosus
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1100359
– volume: 27
  start-page: 86
  year: 2020
  ident: B12
  article-title: Complement and the kidney: An overview
  publication-title: Adv Chronic Kidney Dis
  doi: 10.1053/j.ackd.2019.10.003
– volume: 16
  year: 2020
  ident: B3
  article-title: Protecting the kidney in systemic lupus erythematosus: From diagnosis to therapy
  publication-title: Nat Rev Rheum
  doi: 10.1038/s41584-020-0401-9
– volume: 74
  year: 2013
  ident: B17
  article-title: Deposition of the lectin pathway of complement in renal biopsies of lupus nephritis patients
  publication-title: Hum Immunol
  doi: 10.1016/j.humimm.2013.04.030
– volume: 7
  year: 2016
  ident: B10
  article-title: Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2016.00055
– volume: 245
  year: 2022
  ident: B16
  article-title: Intertwined pathways of complement activation command the pathogenesis of lupus nephritis
  publication-title: Transl Res
  doi: 10.1016/j.trsl.2022.03.005
– volume: 42
  year: 2015
  ident: B41
  article-title: Levels in plasma of the serine proteases and associated proteins of the lectin pathway are altered in patients with systemic lupus erythematosus
  publication-title: J Rheum
  doi: 10.3899/jrheum.141163
– volume: 66
  year: 2015
  ident: B51
  article-title: Adamts13 and Von willebrand factor in thrombotic thrombocytopenic purpura
  publication-title: Annu Rev Med
  doi: 10.1146/annurev-med-061813-013241
– volume: 384
  start-page: 599
  year: 2021
  ident: B55
  article-title: Avacopan for the treatment of anca-associated vasculitis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2023386
– volume: 153
  year: 2022
  ident: B56
  article-title: Complement factor b inhibitor Lnp023 improves lupus nephritis in Mrl/Lpr mice
  publication-title: BioMed Pharmacother
  doi: 10.1016/j.biopha.2022.113433
– volume: 26
  year: 2015
  ident: B48
  article-title: Complement factor C4d is a common denominator in thrombotic microangiopathy
  publication-title: J Am Soc Nephrol
  doi: 10.1681/asn.2014050429
– volume: 344
  year: 2001
  ident: B27
  article-title: Complement. first of two parts
  publication-title: N Engl J Med
  doi: 10.1056/nejm200104053441406
– volume: 39
  year: 2012
  ident: B18
  article-title: The association between the mannose-binding lectin codon 54 polymorphism and systemic lupus erythematosus: A meta-analysis update
  publication-title: Mol Biol Rep
  doi: 10.1007/s11033-011-1361-6
– volume: 21
  start-page: 13
  year: 2012
  ident: B46
  article-title: Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: A pilot study
  publication-title: Lupus
  doi: 10.1177/0961203311422093
– volume: 4
  year: 1994
  ident: B5
  article-title: Renal vascular complications of systemic lupus erythematosus
  publication-title: J Am Soc Nephrol
  doi: 10.1681/asn.V481499
– volume: 71
  year: 2019
  ident: B22
  article-title: European League against Rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus
  publication-title: Arthritis Rheum
  doi: 10.1002/art.40930
– volume: 6
  year: 2016
  ident: B13
  article-title: Masp-3 is the exclusive pro-factor d activator in resting blood: The lectin and the alternative complement pathways are fundamentally linked
  publication-title: Sci Rep
  doi: 10.1038/srep31877
– volume: 40
  year: 2021
  ident: B40
  article-title: Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis
  publication-title: Clin Rheum
  doi: 10.1007/s10067-020-05499-1
– volume: 21
  year: 2022
  ident: B39
  article-title: Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management
  publication-title: Autoimmun Rev
  doi: 10.1016/j.autrev.2022.103072
– volume: 93
  year: 2018
  ident: B23
  article-title: Revision of the international society of Nephrology/Renal pathology society classification for lupus nephritis: Clarification of definitions, and modified national institutes of health activity and chronicity indices
  publication-title: Kidney Int
  doi: 10.1016/j.kint.2017.11.023
– volume: 17
  year: 2006
  ident: B36
  article-title: Factor h and atypical hemolytic uremic syndrome: Mutations in the c-terminus cause structural changes and defective recognition functions
  publication-title: J Am Soc Nephrol
  doi: 10.1681/asn.2005080868
– volume: 12
  year: 2021
  ident: B32
  article-title: The spectrum of C4d deposition in renal biopsies of lupus nephritis patients
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.654652
– volume: 21
  start-page: 245
  year: 2020
  ident: B53
  article-title: A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy
  publication-title: BMC Nephrol
  doi: 10.1186/s12882-020-01888-5
– volume: 15
  start-page: R12
  year: 2013
  ident: B7
  article-title: The spectrum of renal thrombotic microangiopathy in lupus nephritis
  publication-title: Arthritis Res Ther
  doi: 10.1186/ar4142
– volume: 22
  year: 2011
  ident: B45
  article-title: Complement factor h deficiency accelerates development of lupus nephritis
  publication-title: J Am Soc Nephrol
  doi: 10.1681/asn.2010060647
– volume: 8
  year: 2012
  ident: B21
  article-title: Stec-hus, atypical hus and ttp are all diseases of complement activation
  publication-title: Nat Rev Nephrol
  doi: 10.1038/nrneph.2012.195
– volume: 61
  year: 2014
  ident: B37
  article-title: Are complement deficiencies really rare? overview on prevalence, clinical importance and modern diagnostic approach
  publication-title: Mol Immunol
  doi: 10.1016/j.molimm.2014.06.030
– volume: 207
  start-page: 29
  year: 2010
  ident: B43
  article-title: Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor d
  publication-title: J Exp Med
  doi: 10.1084/jem.20090633
– volume: 14
  year: 2005
  ident: B31
  article-title: Factors associated with poor outcomes in patients with lupus nephritis
  publication-title: Lupus
  doi: 10.1191/0961203305lu2238oa
– volume: 18
  year: 2022
  ident: B52
  article-title: Treat-to-Target in systemic lupus erythematosus: Advancing towards its implementation
  publication-title: Nat Rev Rheum
  doi: 10.1038/s41584-021-00739-3
– volume: 196
  year: 2016
  ident: B14
  article-title: Masp-1 and masp-2 do not activate pro-factor d in resting human blood, whereas masp-3 is a potential activator: Kinetic analysis involving specific masp-1 and masp-2 inhibitors
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1501717
– volume: 24
  year: 2013
  ident: B9
  article-title: The pathogenesis of lupus nephritis
  publication-title: J Am Soc Nephrol
  doi: 10.1681/asn.2013010026
– volume: 3
  year: 2002
  ident: B54
  article-title: Eculizumab (Alexion)
  publication-title: Curr Opin Investig Drugs
– volume: 19
  year: 2010
  ident: B47
  article-title: Association between anti-Beta2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: A prospective study of 155 cases
  publication-title: Lupus
  doi: 10.1177/0961203310368409
– volume: 164
  year: 2000
  ident: B44
  article-title: Modulation of renal disease in Mrl/Lpr mice genetically deficient in the alternative complement pathway factor b
  publication-title: J Immunol
  doi: 10.4049/jimmunol.164.2.786
– volume: 83
  year: 2013
  ident: B6
  article-title: Inclusion of renal vascular lesions in the 2003 Isn/Rps system for classifying lupus nephritis improves renal outcome predictions
  publication-title: Kidney Int
  doi: 10.1038/ki.2012.409
– volume: 65
  year: 2004
  ident: B20
  article-title: Effects of complement factor d deficiency on the renal disease of Mrl/Lpr mice
  publication-title: Kidney Int
  doi: 10.1111/j.1523-1755.2004.00371.x
– volume: 46
  year: 2019
  ident: B28
  article-title: Clinical outcomes and clinico-pathological correlations in lupus nephritis with kidney biopsy showing thrombotic microangiopathy
  publication-title: J Rheum
  doi: 10.3899/jrheum.180773
– volume: 19
  year: 2010
  ident: B34
  article-title: Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy
  publication-title: Lupus
  doi: 10.1177/0961203310376523
– volume: 2
  year: 2018
  ident: B49
  article-title: Complement-mediated thrombotic microangiopathy associated with lupus nephritis
  publication-title: Blood Adv
  doi: 10.1182/bloodadvances.2018019596
– volume: 18
  year: 1991
  ident: B35
  article-title: Renal vascular lesions as a marker of poor prognosis in patients with lupus nephritis. gruppo italiano per lo studio Della nefrite lupica (Gisnel)
  publication-title: Am J Kidney Dis
  doi: 10.1016/s0272-6386(12)80885-7
– volume: 20
  year: 2011
  ident: B42
  article-title: Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis
  publication-title: Lupus
  doi: 10.1177/0961203311415561
– volume: 10
  year: 2015
  ident: B15
  article-title: Molecules great and small: The complement system
  publication-title: Clin J Am Soc Nephrol
  doi: 10.2215/cjn.06230614
– volume: 8
  year: 2012
  ident: B1
  article-title: B-cell depletion in the treatment of lupus nephritis
  publication-title: Nat Rev Nephrol
  doi: 10.1038/nrneph.2012.141
– volume: 13
  year: 2017
  ident: B38
  article-title: Redefining lupus nephritis: Clinical implications of pathophysiologic subtypes
  publication-title: Nat Rev Nephrol
  doi: 10.1038/nrneph.2017.85
– volume: 129
  year: 2017
  ident: B50
  article-title: Thrombotic thrombocytopenic purpura
  publication-title: Blood
  doi: 10.1182/blood-2016-10-709857
– volume: 42
  start-page: 19
  year: 2020
  ident: B25
  article-title: Renal microvascular lesions in lupus nephritis
  publication-title: Ren Fail
  doi: 10.1080/0886022x.2019.1702057
– volume: 75
  year: 1983
  ident: B30
  article-title: Prognostic factors in lupus nephritis. contribution of renal histologic data
  publication-title: Am J Med
  doi: 10.1016/0002-9343(83)90338-8
– volume: 76
  year: 1997
  ident: B29
  article-title: Renal vascular lesions in lupus nephritis
  publication-title: Med (Baltimore)
  doi: 10.1097/00005792-199709000-00003
– volume: 12
  year: 2021
  ident: B57
  article-title: Factor d inhibition blocks complement activation induced by mutant factor b associated with atypical hemolytic uremic syndrome and membranoproliferative glomerulonephritis
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.690821
SSID ssj0000493335
Score 2.3761804
Snippet The pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of complement...
ObjectiveThe pathogenesis of thrombotic microangiopathy (TMA) in lupus nephritis (LN) remains complicated. This study aimed to detect the deposition of...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1081942
SubjectTerms alternative pathway
complement
Complement Factor B
Complement Membrane Attack Complex - analysis
Endothelial Cells - metabolism
Humans
Immunology
lectin pathway
Lectins
lupus nephritis
Lupus Nephritis - pathology
Prognosis
Retrospective Studies
Thrombotic Microangiopathies - pathology
thrombotic microangiopathy
von Willebrand Factor
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fa9swEBalMOjLWLd289oOFfpWTB0p_qHHtiyUwfqUQt-EZMmrRyKHOF7JY__z3klOiMfYXvZqWbasO_m-k-6-I-TCcmtENVIxgFUejyvD4yLV4zhnrLBWAGj2SWHf77O7h_G3x_Rxp9QXxoQFeuAwcVeqBKMpFKAYAPMsZZjQwLWuxqXWAE8M_n0Tkew4Uz8D7uWcpyFLBrwwcVXV83kH_iBjGFYHrjsbWCJP2P8nlPl7sOSO9Zm8I2972Eivw3APyZ5178mbUEhy_YG8TJ-WzVw30ErnGGKn3I-6wWrDa-pzQwBQ0kXTLCnGY7mmrVvqywzRWbfoWuosyBTZjeivWlEfZu63DSlu6teOKmeoP1d3niec4pOf1ZpiVkTY0z0iD5Ov09u7uC-uEJdcFKu4AORSsRS-SxlbZhoTTLUueGVyk-kkswY8L12yES_w0BgMmRC4X5qqTKRg0fgx2XeNs58ItVmmVWGSCrnt8Zy2TIUCzxO65MrwIiKjzUTLsmcexwIYMwkeCApHeuFIFI7shRORy22fReDd-OvdNyi_7Z3Ime0vgCbJXpPkvzQpIucb6UtYY3hwopxtulayHGnZcnD9IvIxaMP2VRwgHMKgiOQDPRmMZdji6ifP4y1ywKZ58vl_DP6EHOCEYKDNiJ-S_dWys2cAl1b6i18Zr69AFPQ
  priority: 102
  providerName: Directory of Open Access Journals
Title Thrombotic microangiopathy mediates poor prognosis among lupus nephritis via complement lectin and alternative pathway activation
URI https://www.ncbi.nlm.nih.gov/pubmed/36582241
https://www.proquest.com/docview/2759957260
https://pubmed.ncbi.nlm.nih.gov/PMC9792970
https://doaj.org/article/ac0649a91601425286243bbf4cbb019d
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELamTUi8IH4TBpOReEOBxk6c-AFNAzEmpPG0Sn2z7NjZglqnJM2gj_znu3PSiqKBxEulNr9zdu_7znffEfLacWdllegYwCqP08ryuMhMGueMFc5JAM2hKOz8qzibpl9m2WyPbNodjS-wu5XaYT-paTt_-_P7-hgm_HtknOBv31X1YtED1WMMM-aAlcNf8gF4JoFk7HyE-98GNMx56LmZCJHGMJbToY7mL6fZ8VVB0v82HPpnOuVv_un0Prk3Akt6MoyEB2TP-YfkztBqcv2I_Lq4apuFaWArXWASnvaXdYP9iNc0VI8A5KTLpmkpZmz5pqs7GhoR0Xm_7DvqHVgd9Y_oda1pSEQPgUWKYf_aU-0tDSvvPiiJUzzzD72mWDcxRH0fk-npp4uPZ_HYfiEuuSxWcQHYpmIZPJe2rhQGS1CNKXhlcyvMRDgL3MyULOEFLiuDq5MSI6qZFjIDn8efkH3fePeMUCeE0YWdVKh-jyu5ZSY1cFM4JNeWFxFJNi9alaM2ObbImCvgKGgcFYyj0DhqNE5E3myPWQ7KHP_c-wPab7snqmqHH5r2Uo2TVOkSAJrUgJiBOLKMYfEMN6ZKS2PgVm1EXm2sr2AW4tKK9q7pO8VyFG7LgRxG5OkwGraX4gDyEChFJN8ZJzv3srvF11dB6VvmgF7zyfP_etRDche_Ys5Nwl-Q_VXbu5eAnFbmKEQc4PPzLDkKU-MGo4UZlw
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Thrombotic+microangiopathy+mediates+poor+prognosis+among+lupus+nephritis+via+complement+lectin+and+alternative+pathway+activation&rft.jtitle=Frontiers+in+immunology&rft.au=Zhang%2C+Binshan&rft.au=Xing%2C+Guolan&rft.date=2022-12-13&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=13&rft_id=info:doi/10.3389%2Ffimmu.2022.1081942&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2022_1081942
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon